Retatrutide + Cagrilintide
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Retatrutide + cagrilintide is a vendor-assembled pairing of two distinct investigational metabolic peptides. Retatrutide is a single-molecule “triple agonist” that acts on the GIP, GLP-1, and glucagon receptors, and has drawn attention for the large weight reductions reported in its phase 2 obesity trial. Cagrilintide is a long-acting amylin analog most studied in combination with semaglutide, a pairing developed commercially as CagriSema.
The two compounds have robust individual data but no shared clinical record. There are no published human trials of retatrutide combined with cagrilintide, so the “quad-pathway” framing used in the research-chemical market is a marketing description rather than a studied protocol.
Both components remain investigational. Neither is approved by the FDA or any major regulator, and the combination is sold for laboratory research only.
How it works
Retatrutide engages three receptors simultaneously: GLP-1 and GIP, which are incretin pathways tied to appetite and glucose handling, and glucagon, which is thought to add an energy-expenditure component. Cagrilintide works through a separate mechanism, mimicking the pancreatic hormone amylin to influence satiety, slow gastric emptying, and complement GLP-1-based signaling.
The rationale vendors give for stacking them is that amylin agonism operates on a pathway the triple agonist does not directly cover. Whether these mechanisms combine additively, redundantly, or with compounded side effects in humans has not been established, since the two have only been studied separately.
Reported benefits
- Substantial body-weight reduction reported for retatrutide in phase 2 obesity studies
- Improvements in glycemic markers and prediabetes reversal observed with retatrutide
- Additional weight loss and satiety effects studied for cagrilintide, mainly alongside semaglutide
- Vendors claim complementary appetite and metabolic pathways from combining the two
These are effects reported for the individual compounds, not outcomes demonstrated for the combination.
Considerations & side effects
The most consistently reported side effects across both peptide classes are gastrointestinal — nausea, vomiting, and diarrhea — which tend to track with dose and escalation speed. Combining two appetite- and gut-acting agents could plausibly amplify these effects, but there is no combination safety data to draw on.
Because no human study has evaluated retatrutide with cagrilintide together, the interaction profile, long-term safety, and appropriate use of this pairing are unknown. Product purity and labeling vary widely in the research-chemical market, and this material is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is retatrutide + cagrilintide?
It is a vendor-marketed pairing of two separate investigational metabolic peptides: retatrutide, a triple agonist of the GIP, GLP-1, and glucagon receptors, and cagrilintide, a long-acting amylin analog. Sellers describe the stack as a 'quad-pathway' approach, but the two have not been studied together as a combination in humans.
Is this combination FDA-approved?
No. Neither retatrutide nor cagrilintide is FDA-approved, and the two together have not been evaluated in any registered clinical trial. Both are investigational compounds sold for research purposes only.
Has the retatrutide and cagrilintide combination been studied in people?
Not as a pair. Each peptide has its own clinical data — retatrutide in phase 2 obesity trials and cagrilintide alongside semaglutide (CagriSema) — but there are no published human studies of retatrutide combined with cagrilintide.
How do the two components differ?
Retatrutide acts on three incretin and glucagon pathways at once, while cagrilintide mimics amylin, a hormone involved in satiety and gastric emptying. Vendors combine them to target distinct mechanisms, though the safety of doing so is uncharacterized.
References
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. ↗
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a phase 2 trial. Lancet. 2023. ↗
- Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. PMC. 2024. ↗
Related compounds
Weight blend combining the amylin analog cagrilintide with the GIP/GLP-1 dual agonist tirzepatide, targeting satiety and glycemic pathways together. No human trial of this exact combination; research-level, sold pre-blended.
Dual-mechanism weight blend pairing the long-acting amylin analog cagrilintide with the GLP-1 agonist semaglutide (1:1). Novo Nordisk's clinical program showed greater weight loss than either component alone. Sold as a single co-lyophilized vial.
Compounded GLP-1 weight formulation adding vitamin B12 (often with glycine) to semaglutide, marketed to support energy and offset GLP-1 fatigue. Widely offered by US compounding pharmacies and telehealth clinics.